Log In
Print
BCIQ
Print
Print this Print this
 

LGT209

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionLipid modulator
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHypercholesterolemia
Indication DetailsTreat hypercholesterolemia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today